Masked Hypertension Diagnosis and Management

Introduction to Masked Hypertension

The American Heart Association notes that when clinic readings are lower than home readings in a patient with a history of white coat hypertension, this represents a "reverse white coat effect" or masked hypertension, which carries cardiovascular risk similar to sustained hypertension and requires treatment initiation or intensification 1, 2, 3
Masked hypertension is associated with twice the cardiovascular disease risk of normotensives, and home blood pressure provides better cardiovascular risk prediction than office measurements 1, 3

The European Society of Cardiology recommends that Ambulatory Blood Pressure Monitoring (ABPM) is the gold standard for confirming masked hypertension and should be obtained before making treatment decisions, detecting masked hypertension with 25.8% prevalence versus only 11.1% with home monitoring alone 5
Masked hypertension is confirmed when office BP <140/90 mmHg but daytime ambulatory BP ≥135/85 mmHg or 24-hour ambulatory BP ≥130/80 mmHg 4
Home blood pressure monitoring validation requires proper technique: discard first day readings, take measurements both morning and evening, obtain minimum 12 readings over 7 days, with a threshold for hypertension of ≥135/85 mmHg 1, 2, 6

The American College of Cardiology recommends initiating pharmacological treatment if masked hypertension is confirmed, as this condition carries cardiovascular risk equivalent to sustained hypertension, with a target systolic BP 120-129 mmHg for most adults, or reduce BP by at least 20/10 mmHg from baseline 7
Lifestyle modifications, including sodium restriction to <1500 mg/day, DASH diet, and regular aerobic exercise 90-150 minutes/week, should be implemented concurrently with pharmacotherapy 7
Home BP <135/85 mmHg or 24-hour ambulatory BP <130/80 mmHg should be used as treatment goals 4

The European Society of Hypertension recommends continuing out-of-office BP monitoring (home or ambulatory) every 3-6 months to assess treatment response, and reassess for target organ damage which would justify more aggressive treatment 2, 4, 6
Monitor for conversion to sustained hypertension, which occurs at 1-5% per year in patients with masked hypertension 4